Ohcanbohtosat - Debbie Robbrecht

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid... Dahkki Joaquina C. Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean‐Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose deMiguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F. Stephen Hodi

Viečča ollesdeavstta

Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical stu... Dahkki Debbie Robbrecht, Jean‐Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger, Ivan Borbath, Marcus O. Butler, Tina Cheng, Patricia Martin Romano, Elvire Pons‐Tostivint, Massimo Di Nicola, Giuseppe Curigliano, Min‐Hee Ryu, Alejo Rodriguez‐Vida, Dirk Schadendorf, Elena Garralda, Giovanni Abbadessa, Brigitte Demers, Amele Amrate, Hong Wang, Joon Sang Lee, Robert Pomponio, Rui Wang

Viečča ollesdeavstta

Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045 Dahkki Anke Richters, Britt Suelmann, Mira Franken, Niven Mehra, Bart Rikhof, Hans Westgeest, Katja Aben, Debbie Robbrecht, Lambertus Kiemeney, Joost Boormans, Toine van der Heijden, Richard Meijer, Tom Arends, Saskia van der Meer, Filip Delaere, André Vis, Carl Wijburg, Ilze van Onna, Diederik Somford, Bart Wijsman, Thomas Kerkhofs, Joan van den Bosch, Annemarie Leliveld-Kors, Katja Goossens- van der Laan, Gerd-Jan Molijn, Luc Roelofs, Martijn Steffens, Tom Hermans, Marleen Duizer

Viečča ollesdeavstta